SEC Form SC 13G/A filed by Alector Inc. (Amendment)
$ALEC
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/28/2025 | $3.50 | Neutral → Outperform | Mizuho |
| 12/17/2024 | $9.00 → $2.50 | Outperform → Neutral | Mizuho |
| 12/16/2024 | $4.00 | Buy → Hold | Stifel |
| 12/4/2024 | $9.00 → $1.00 | Neutral → Underperform | BofA Securities |
| 11/29/2024 | $35.00 → $7.00 | Buy | H.C. Wainwright |
| 11/26/2024 | $10.00 → $3.00 | Equal-Weight → Underweight | Morgan Stanley |
| 12/14/2023 | $8.00 → $15.00 | Hold → Buy | Stifel |
| 12/12/2023 | $12.00 | Buy | Deutsche Bank |
Mizuho upgraded Alector from Neutral to Outperform and set a new price target of $3.50
Mizuho downgraded Alector from Outperform to Neutral and set a new price target of $2.50 from $9.00 previously
Stifel downgraded Alector from Buy to Hold and set a new price target of $4.00
SCHEDULE 13G/A - Alector, Inc. (0001653087) (Subject)
10-Q - Alector, Inc. (0001653087) (Filer)
8-K - Alector, Inc. (0001653087) (Filer)
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
4 - Alector, Inc. (0001653087) (Issuer)
On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease expected to complete in 2026 Continuing to progress Alector Brain Carrier programs, including the company's anti-amyloid beta antibody, engineered GCase enzyme replacement therapy, and anti-tau siRNA $307.3 million in cash, cash equivalents, and investments provides runway into the second half of 2027 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NE
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2025, and provide a mid-year business update. The call will feature remarks from Ryan Darby, M.D., Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center, who will speak on the unmet need in frontotemporal dementia. A press release deta
-- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that its Chief Financial Officer (CFO), Marc Grasso, M.D., will conclude his tenure with the company, effective June 20, 2025, to pursue other opportunities. Neil Berkley, M.B.A., the company's Chief Business Officer, will assume the role of Interim CFO while continuing in his current position. "Marc has been a valuab
SC 13G - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)
SC 13G/A - Alector, Inc. (0001653087) (Subject)
On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer's disease expected to complete in 2026 Continuing to progress Alector Brain Carrier programs, including the company's anti-amyloid beta antibody, engineered GCase enzyme replacement therapy, and anti-tau siRNA $307.3 million in cash, cash equivalents, and investments provides runway into the second half of 2027 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NE
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2025, and provide a mid-year business update. The call will feature remarks from Ryan Darby, M.D., Associate Professor of Neurology and Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center, who will speak on the unmet need in frontotemporal dementia. A press release deta
Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates, including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer's disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2024 financial results and recent portfolio and business updates. As of March 31, 202
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Romano will lead the company's global clinical development strategy, including oversight of the clinical development, clinical operations, biometrics and digital science, and medical affairs functions. Dr. Romano will report to Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development of Alector. Dr. Romano's appointment is effective May 23, 2022. "We are delighted to welcome Gary to our executive leadership tea
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced the appointment of Marc Grasso, M.D., as Chief Financial Officer (CFO). Dr. Grasso brings extensive biotechnology industry leadership experience, including a successful track record in finance, corporate development and strategic leadership. As Alector's CFO, Dr. Grasso will lead all aspects of the company's financial operations and play a critical role in supporting corporate strategy. Dr. Grasso will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector.